C-CAR031

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameC-CAR031
Drug Alias NameTargeting GPC3 armored CART cell injection靶向GPC3装甲型嵌合抗原受体自体T细胞注射液C-CARC-CAR031TC-CAR-031TC-CAR031 +[7] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionAnti-Glypican-3T lymphocyte replacementsImmunologic cytotoxicity +[4] 
TargetsGlypican-3Transforming growth factor beta receptor 2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcZhejiang UniversityShanghai Cellular Biopharmaceutical Group Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A